Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

(2016) Kalijn F. Bol et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Neo approaches to cancer vaccines

(2015) L. Delamarre et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

(2015) Kalijn F Bol et al.   OncoImmunology

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

(2015) Kalijn F Bol et al.   OncoImmunology

Clinical use of dendritic cells for cancer therapy

(2014) Sébastien Anguille et al.   LANCET ONCOLOGY

Dendritic-Cell-Based Therapeutic Cancer Vaccines

(2013) Karolina Palucka et al.   IMMUNITY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Challenges of Guarantee-Time Bias

(2013) Anita Giobbie-Hurder et al.   JOURNAL OF CLINICAL ONCOLOGY

Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

(2012) Erik H. J. G. Aarntzen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma

(2012) E. H. J. G. Aarntzen et al.   CANCER RESEARCH

Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination

(2012) E. H. J. G. Aarntzen et al.   CANCER RESEARCH

Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

(2012) E. H. J. G. Aarntzen et al.   CLINICAL CANCER RESEARCH

International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?

(2012) Friederike Erdmann et al.   INTERNATIONAL JOURNAL OF CANCER

Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment

(2011) A. M. Lesokhin et al.   CANCER RESEARCH

Landmark Analysis at the 25-Year Landmark Point

(2011) Urania Dafni  

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

(2011) W. J. Lesterhuis et al.   CLINICAL CANCER RESEARCH

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

(2010) W. Joost Lesterhuis et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Utility of adjuvant systemic therapy in melanoma

(2009) A. M. M. Eggermont et al.   ANNALS OF ONCOLOGY

In situ Expression of Tumor Antigens by Messenger RNA-Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients

(2009) D. H. Schuurhuis et al.   CANCER RESEARCH

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY